EWEdwards Lifesciences
$84.37-2.77%Real quote · delayedHeart valvesMedtech & life sciences · 10 peers →🏛️ Company factsSEC filings + FINRA official data
Annual revenue $6.1B · latest quarter up 13.6% YoY · profitable (FY net income $1.1B) · short activity within its normal range.
FY revenue
$6.1B
2025-12
Latest Q YoY
+13.6%
Gross margin
78%
FY net income
$1.1B
Diluted EPS
$1.84
Short volume
43.4%
20d avg 43.2% · normal
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-04-29passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-26passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability High · 83/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$0.78 vs $0.73+6.85%
- Mar 2026$0.78 vs $0.75+4%
- Dec 2025$0.58 vs $0.62-6.45%
- Sep 2025$0.67 vs $0.59+13.56%
The takeaway
This company habitually beats by +4.5% — the next report has to clear that bar to count as good news.
Analyst estimates, not our forecast · not investment advice
What's moving this stock lately
No recent news affecting this stock
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
3 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →